TISSUE KALLIKREIN-1 FOR TREATING CHRONIC KIDNEY DISEASE

Provided are methods of using human tissue kallikrein-1 (KLK1) to treat chronic kidney disease (CKD) in patients having salt-sensitive hypertension and low KLK1 levels, including methods of identifying and treating optimal sub-populations of CKD patients based on selected genotypes and/or phenotypes...

Full description

Saved in:
Bibliographic Details
Main Authors PAULS, Rick, Wambeke, David, Paulson, Nick
Format Patent
LanguageEnglish
Published 28.12.2023
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS OR TEST PAPERS THEREFOR
CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MUTATION OR GENETIC ENGINEERING
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROCESSES OF PREPARING SUCH COMPOSITIONS
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:Provided are methods of using human tissue kallikrein-1 (KLK1) to treat chronic kidney disease (CKD) in patients having salt-sensitive hypertension and low KLK1 levels, including methods of identifying and treating optimal sub-populations of CKD patients based on selected genotypes and/or phenotypes.
Bibliography:Application Number: US202318295991